SCHEMBL3480888

SCHEMBL3480888

N#CCC(=O)c1cccc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
MAPT P10636 6/20 0.64
HPGD P15428 4/20 0.64
HSP90AA1 P07900 1/20 0.64
HTT P42858 1/20 0.64
PTPN1 P18031 1/20 0.61
NR4A1 P22736 1/20 0.53
NR4A2 P43354 1/20 0.53
NR4A3 Q92570 1/20 0.53
KDM4E B2RXH2 3/20 0.53
MEN1 O00255 2/20 0.53
GMNN O75496 2/20 0.53
LMNA P02545 2/20 0.53
POLB P06746 2/20 0.53
MAPK1 P28482 2/20 0.53
BLM P54132 2/20 0.53
PMP22 Q01453 2/20 0.53
KMT2A Q03164 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
CMKLR1 Q99788 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29367164 0.84 PTPN1 (0.62) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL395494 0.82 MAPT (0.56) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL26905279 0.81 CYP1B1 (0.57) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL29457006 0.79 PTPN1 (0.71) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL5857951 0.79 PTPN1 (0.71) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL11435010 0.78 ALDH1A1 (1.00) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL1448941 0.77 PTPN1 (0.69) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL11713079 0.77 PTPN1 (0.69) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL30375866 0.77 PTPN1 (0.69) ALDH1A1MAPTHPGDHSP90AA1HTT
SCHEMBL5678914 0.76 KMT2A (0.54) ALDH1A1MAPTHPGDHSP90AA1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974721-B Method for synthesizing 2-carbonyl substituted nitrile compound through 2, 2-trifluoroethyl ketone 平顶山学院 2024-07-02 CN claimed
CN-115974721-A Method for synthesizing 2-carbonyl substituted nitrile compound through 2,2,2-trifluoroethyl ketone 平顶山学院 2023-04-18 CN claimed
CN-115974721-B Method for synthesizing 2-carbonyl substituted nitrile compound through 2, 2-trifluoroethyl ketone 平顶山学院 2024-07-02 CN disclosed
CN-115974721-A Method for synthesizing 2-carbonyl substituted nitrile compound through 2,2,2-trifluoroethyl ketone 平顶山学院 2023-04-18 CN disclosed
CN-107024834-B Compound and coloring composition 住友化学株式会社 2021-11-23 CN disclosed
EP-3536692-B1 PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME MILLENNIUM PHARM INC (US) 2021-04-07 EP disclosed
EP-3536692-B1 PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME MILLENNIUM PHARM INC (US) 2021-04-07 EP disclosed
CN-107586469-B Pigment composition, coloring composition, and coloring curable composition 住友化学株式会社 2021-04-06 CN disclosed
EP-3536692-A1 PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME Millennium Pharmaceuticals, Inc. (US) 2019-09-11 EP disclosed
EP-3536692-A1 PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME Millennium Pharmaceuticals, Inc. (US) 2019-09-11 EP disclosed
EP-3173413-B1 PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME MILLENNIUM PHARM INC (US) 2019-05-01 EP disclosed
US-20020143004-A1 Allosteric adenosine receptor modulators KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. 2002-10-03 US disclosed
WO-2002074056-A2 ALLOSTERIC ADENOSINE RECEPTOR MODULATORS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC. (US) 2002-09-26 WO disclosed
US-20010047008-A1 Allosteric adenosine receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2001-11-29 US disclosed
US-5578711-A Process for the preparation of dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1996-11-26 US disclosed
US-5541299-A Process for the preparation of dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1996-07-30 US disclosed
US-5502171-A Process for the preparation of dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1996-03-26 US disclosed
EP-0459830-A1 Pharmacologically active CNS compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-12-04 EP disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed
US-3933423-A Azoic dyeing of leather E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047008-A1 Allosteric adenosine receptor modulators ADORA2A, ADORA1, ADORA2B ALDH1A1 291/4885MAPT 4793/4885HPGD 972/4885
US-20020143004-A1 Allosteric adenosine receptor modulators ADORA2A, ADORA1, ADORA2B ALDH1A1 328/4885MAPT 4839/4885HPGD 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.